aTYR PHARMA INC

ATYR

aTYR PHARMA INC

ATYR

Insider Sentiment (TTM):

Last Purchase:2026-05-27Last Sale:2026-02-04Shares Purchased (TTM):417,999Shares Sold (TTM):6,421

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:54,805,892Shares Outstanding:98,043,839Institutional Ownership Pct.:55.90%

Earnings Market Reaction:

Filing Date:2026-08-07Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	16	10	11	6	17	10	11	11	7	7	23	10
Available For Sale Securities Debt Securities Curr…	41	57	68	84	63	66	61	55	72	78	76	92
Other Receivables Net Current	0	0	1	1	0	1	2	2	2	2	2	2
Prepaid Expense Current	1	1	1	2	7	6	8	8	10	10	2	3
Assets Current	58	68	80	93	87	83	82	76	90	97	103	107
Restricted Cash Noncurrent	1	2	2	3	3	2	3	3	3	3	3	3
Property Plant And Equipment Net	4	4	4	4	5	5	5	5	5	5	6	6
Operating Lease Right Of Use Asset	5	5	6	6	6	6	6	6	6	6	7	7
Finance Lease Right Of Use Asset	-	0	1	1	1	1	1	1	1	2	2	2
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	70	80	93	107	102	97	97	92	106	113	121	125
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	3	3	4	4	4	2	4	4	1	5	4	2
Accrued Liabilities Current	7	7	10	10	10	8	9	9	9	10	12	10
Operating Lease Liability Current	1	1	1	1	1	1	1	1	1	1	1	1
Finance Lease Liability Current	-	1	1	1	1	1	1	1	1	1	0	0
Liabilities Current	11	12	15	16	16	11	15	14	12	16	16	13
Operating Lease Liability Noncurrent	10	10	10	11	11	11	11	11	12	12	12	13
Finance Lease Liability Noncurrent	-	0	0	0	1	1	1	1	1	1	1	1
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	676	675	674	672	641	622	602	582	582	568	559	552
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	-0	-0	-0	-0	-0	0	-0	-0	-0	-0
Retained Earnings Accumulated Deficit	-627	-617	-606	-592	-566	-547	-532	-517	-500	-484	-468	-453
Stockholders Equity	49	58	67	80	75	75	70	65	82	84	90	98
Minority Interest	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Liabilities And Stockholders Equity	70	80	93	107	102	97	97	92	106	113	121	125
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	340	170	170	170	170	170	170	170	170	170	170	170
Common Stock Shares Issued	98	98	98	98	93	89	84	76	76	68	63	59
Shares Outstanding	98	98	98	98	93	89	84	76	76	68	63	59

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-6.75%	17.66%	-3.57%	-	-	-	-	-	-	-	-	-
2025	41.46%	59.18%	84.49%	2.67%	-83.95%	-81.56%	1.43%	-3.51%	-6.10%	-16.63%	-12.97%	-45.68%
2024	12.50%	-6.88%	2.50%	8.05%	7.47%	74.71%	13.87%	20.65%	15.81%	-34.34%	-9.77%	12.03%
2023	-	-	-	-13.27%	-19.39%	-38.78%	10.43%	22.61%	37.39%	14.81%	-0.62%	6.79%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	5.12	5.78	5.30	5.93	5.63	7.79	5.48	5.41	7.63	6.07	6.27	8.33
Quick Ratio	5.08	5.73	5.25	5.82	5.21	7.24	4.93	4.80	6.77	5.44	6.13	8.09
Working Capital	46.97M	55.88M	65.09M	77.34M	71.96M	72.59M	66.99M	62.20M	78.46M	80.94M	86.58M	94.42M
Leverage & Debt
Debt to Equity	0.23	0.20	0.23	0.20	0.21	0.14	0.21	0.22	0.15	0.19	0.18	0.13
Debt Ratio	0.16	0.15	0.16	0.15	0.15	0.11	0.15	0.15	0.11	0.14	0.14	0.10
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10
Per Share Metrics
Diluted EPS TTM	-0.62	-0.71	-0.80	-0.77	-0.74	-0.73	-0.86	-0.84	-0.80	-0.82	-0.94	-0.75
Free Cash Flow Per Share TTM	-0.56	-0.60	-0.67	-0.65	-0.62	-0.72	-0.93	-0.89	-0.89	-0.88	-0.70	-0.65
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-33,609.47%	-38,573.68%	-40,856.32%	-41,395.26%	-	-	-28,899.57%	-28,958.72%	-10,633.50%	-9,994.56%	-15,557.79%	-436.82%
Net Profit Margin TTM	-32,003.16%	-36,857.37%	-39,009.47%	-39,542.11%	-	-	-27,243.83%	-27,156.60%	-9,847.11%	-9,172.28%	-14,276.77%	-401.84%
Growth Metrics
Net Revenue Growth (1Y)	-	-	-19.15%	-19.15%	-100.00%	-100.00%	-33.43%	-97.81%	-94.34%	-94.34%	-96.60%	-
Net Income Growth (1Y)	-8.76%	10.43%	15.77%	17.73%	15.10%	17.58%	27.04%	47.88%	28.51%	19.48%	11.15%	-6.96%
EPS Growth (1Y)	-16.15%	-2.59%	-7.54%	-8.15%	-7.68%	-10.16%	-8.30%	12.93%	-1.97%	-24.25%	-41.08%	-53.93%
Valuation Metrics
P/E TTM	-0.96	-1.09	-0.98	-0.93	-6.86	-4.12	-4.20	-2.09	-1.95	-2.39	-1.50	-2.12
P/B TTM	1.20	1.32	1.08	0.88	6.12	3.49	3.85	2.04	1.38	1.53	0.84	0.93
P/S TTM	308.15	402.50	383.20	368.67	-	-	1,143.94	567.71	191.77	219.14	214.12	8.52
Market Cap	58.55M	76.47M	72.81M	70.05M	456.91M	261.19M	268.83M	133.41M	112.76M	128.86M	75.59M	91.46M
Enterprise Value	42.39M	67.21M	62.95M	64.93M	440.85M	252.12M	259.20M	123.51M	107.64M	123.85M	54.97M	83.57M
Calculated Values
Free Cash Flow TTM	-54.82M	-59.30M	-62.06M	-62.99M	-55.65M	-62.21M	-69.18M	-67.11M	-64.05M	-58.00M	-37.44M	-37.85M
Net Debt	-16.16M	-9.26M	-9.85M	-5.12M	-16.06M	-9.07M	-9.63M	-9.90M	-5.12M	-5.00M	-20.62M	-7.89M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-27Purchase

Owner: Schimmel, Paul

Title: -

Shares: 100,000

Price/Share: $0.50

Value: $50,000.00

Shares Owned: 779,143

Relationship: Director

Ownership: Indirect

2026-02-04Sale

Owner: Denyes, Nancy

Title: General Counsel

Shares: 1,118

Price/Share: $0.98

Value: $1,095.64

Shares Owned: 33,124

Relationship: Officer

Ownership: Direct

2026-02-04Sale

Owner: Shukla, Sanjay

Title: President and CEO

Shares: 3,745

Price/Share: $0.98

Value: $3,670.10

Shares Owned: 153,553

Relationship: Director,Officer

Ownership: Direct

2026-02-04Sale

Owner: Broadfoot, Jill Marie

Title: Chief Financial Officer

Shares: 1,558

Price/Share: $0.98

Value: $1,526.84

Shares Owned: 37,296

Relationship: Officer

Ownership: Direct

2025-10-09Purchase

Owner: Schimmel, Paul

Title: -

Shares: 317,999

Price/Share: $0.94

Value: $298,919.06

Shares Owned: 1,413,023

Relationship: Director

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-27	Schimmel, Paul	Director	-	Indirect	Purchase	100,000	0.50	$50,000.00	779,143	4
2026-02-04	Denyes, Nancy	Officer	General Counsel	Direct	Sale	1,118	0.98	$1,095.64	33,124	4
2026-02-04	Shukla, Sanjay	Director,Officer	President and CEO	Direct	Sale	3,745	0.98	$3,670.10	153,553	4
2026-02-04	Broadfoot, Jill Marie	Officer	Chief Financial Officer	Direct	Sale	1,558	0.98	$1,526.84	37,296	4
2025-10-09	Schimmel, Paul	Director	-	Indirect	Purchase	317,999	0.94	$298,919.06	1,413,023	4
2025-03-17	Gross, Jane A	Director	-	Direct	Purchase	3,750	4.00	$15,000.00	9,750	4
2025-02-04	Broadfoot, Jill Marie	Officer	Chief Financial Officer	Direct	Sale	1,254	3.78	$4,740.12	31,763	4
2025-02-04	Denyes, Nancy	Officer	General Counsel	Direct	Sale	899	3.78	$3,398.22	26,555	4
2024-07-24	Schimmel, Paul	Director	-	Indirect	Purchase	52,300	1.93	$100,939.00	413,023	4
2024-06-05	Denyes, Nancy	Officer	General Counsel	Direct	Purchase	5,000	1.86	$9,300.00	22,267	4
2024-05-31	Broadfoot, Jill Marie	Officer	Chief Financial Officer	Direct	Purchase	5,000	1.79	$8,950.00	27,960	4
2024-05-31	Shukla, Sanjay	Director,Officer	President and CEO	Direct	Purchase	20,000	1.81	$36,200.00	136,548	4
2024-05-30	Coughlin, Timothy	Director	-	Indirect	Purchase	50,000	1.75	$87,500.00	56,000	4
2024-02-06	Broadfoot, Jill Marie	Officer	Chief Financial Officer	Direct	Sale	1,590	1.69	$2,687.10	20,821	4
2023-12-12	Shukla, Sanjay	Director,Officer	President and CEO	Direct	Purchase	12,000	1.18	$14,160.00	106,173	4
2023-11-13	Shukla, Sanjay	Director,Officer	President and CEO	Direct	Purchase	13,578	1.11	$15,071.58	91,173	4
2023-07-28	Shukla, Sanjay	Director,Officer	President and CEO	Direct	Purchase	15,000	2.01	$30,150.00	76,173	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

55.90%

Inst. Shares: 54,805,892

Shares Outstanding: 98,043,839

2025-12-31

54.83%

Inst. Shares: 50,979,430

Shares Outstanding: 92,985,359

2025-09-30

62.93%

Inst. Shares: 61,140,183

Shares Outstanding: 97,153,541

2025-06-30

72.37%

Inst. Shares: 65,221,180

Shares Outstanding: 90,120,235

2025-03-31

66.26%

Inst. Shares: 57,308,251

Shares Outstanding: 86,485,126

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	54,805,892	98,043,839	55.90%
2025-12-31	50,979,430	92,985,359	54.83%
2025-09-30	61,140,183	97,153,541	62.93%
2025-06-30	65,221,180	90,120,235	72.37%
2025-03-31	57,308,251	86,485,126	66.26%
2024-12-31	54,402,339	74,261,265	73.26%
2024-09-30	47,431,229	75,801,666	62.57%
2024-06-30	47,742,460	72,284,351	66.05%
2024-03-31	39,627,074	66,080,593	59.97%
2023-12-31	40,099,433	53,606,488	74.80%
2023-09-30	36,578,693	57,885,393	63.19%
2023-06-30	35,142,028	55,143,805	63.73%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

aTYR PHARMA INC (ATYR) — SEC Financial Statements & Analysis

aTYR PHARMA INC (ATYR) is a biological products, (no diagnostic substances) company, incorporated in DE. aTYR PHARMA INC trades on Nasdaq as: ATYR. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), aTYR PHARMA INC reported a -19.15% year-over-year revenue growth, a Debt-to-Equity ratio of 0.23x, a Price-to-Sales (P/S) ratio of 308.15x (TTM), a Price-to-Book (P/B) ratio of 1.20x (TTM), at a market cap of $58.55M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -19.15%
Debt To Equity: 0.23x
P/S TTM: 308.15x
P/B TTM: 1.20x
Market Cap: $58.55M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is aTYR PHARMA INC in?

aTYR PHARMA INC (ATYR) operates in the Biological Products, (No Diagnostic Substances) industry.

What is ATYR's market cap?

aTYR PHARMA INC (ATYR) has a market capitalization of $58.55M as of 2026-06-30.

What exchange does ATYR trade on?

aTYR PHARMA INC (ATYR) trades on the Nasdaq.

Where is aTYR PHARMA INC incorporated?

aTYR PHARMA INC is incorporated in DE.

aTYR PHARMA INC

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

aTYR PHARMA INC (ATYR) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.
Main Street's price.

aTYR PHARMA INC (ATYR) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.